By staying up-to-date on new approaches and options for neoadjuvant /adjuvant systemic therapy, the clinicians will be able to provide appropriate care using a shared decision-making process with the patient, taking into account patient and disease characteristics including risk of recurrence, and weighing the potential benefits and risks of each option. In addition, it is important for clinicians to be aware of new supportive care interventions available to improve the quality of life of patients.

Clinicians need to recognize that these disparities exist and the causes for the disparities to optimally manage their patients with breast cancer.

Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practice remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which agents already exist or are currently being developed. Within recent years, PD-L1 inhibition is being studied in trials as a new avenue for treatment options in these patients. Current evidence demonstrates increased benefit when using these agents in combination with chemotherapy.

This program will provide expert insights on the current recommendations of care for patients with breast cancer and include the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

Being familiar with the current management of breast cancer will help clinicians support their patients and to communicate with specialists in the multidisciplinary team.

The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.

Pharmacists should be aware of the new data and recommendations surrounding novel agents and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.

Being familiar with the current management of breast cancer will help clinicians support their patients and to communicate with specialists in the multidisciplinary team.